Erin Enright and Alfonso “Chito” Zulueta appointed to board of directors
New board members bring skills and experience aligned with business strategy
Per Wold-Olsen appointed chairman of the board
David Stack and Joe Zakrzewski leave the board
Actions reflect company and board commitment to continuous refresh and improvement
DUBLIN, Ireland and BRIDGEWATER, NJ, May 19, 2022 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN) today announced a series of appointments and leadership changes to its Board of Directors, including:
- Appointment of Erin Enright and Alfonso “Chito” Zulueta to the Board of Directors, effective immediately. Ms. Enright and Mr. Zulueta will stand for re-election to the board at the company’s 2022 annual meeting in June.
- Per Wold-Olsen, director since January 2022, has been appointed Chairman of the Board, effective immediately. Mr Wold-Olsen will stand for re-election to the board at the company’s 2022 annual meeting in June.
- As part of a planned retirement, David Stack, director since 2012, and Joe Zakrzewski, director since 2010, will retire from the board, effective at the close of the 2022 annual meeting.
- Mr. Wold-Olsen was appointed Chairman of the Compensation Committee; Ms. Enright has been appointed Chair of the Audit Committee.
- Dr. Lars Ekman will remain a member of the board.
“Today’s announcement advances the company’s ongoing efforts launched in October 2021 to broaden the expertise and diversity of our board and company. These board changes demonstrate our commitment to Amarin’s strategic plan to drive sustainable and profitable growth, and ensure that we have the additional skills and experience to support Amarin’s current strategy, including including significant experience in finance, technology, portfolio diversification, operational excellence, and international and strategic business operations,” said Mr. Wold-Olsen. “Erin and Alfonso are both highly respected leaders with proven track records in their respective fields and bring strong and relevant expertise to help drive the continued execution of our three-pillar growth strategy. Erin’s deep experience in investment banking and capital markets, particularly in healthcare, and Alfonso’s unique knowledge of international markets and global marketing will allow them to add value immediately. value to our board.
Mr. Wold-Olsen continued, “On behalf of the entire Board of Directors, I would like to thank Lars for his unwavering leadership as Chairman over the past eight years, during which Amarin achieved one of the largest cardiovascular outcome trials in recent times. I am pleased that we continue to benefit from his valuable knowledge as a permanent member of our Board of Directors. We also express our deepest gratitude to David and Joe for their distinguished service and countless contributions to Amarin over the years.
Ms. Enright brings over 30 years of experience as an executive and investor in a healthcare company. She is currently a Managing Partner at Prettybrook Partners, overseeing approximately 20 active investments in various healthcare companies. Prior to her role at Prettybrook, Ms. Enright served as Chief Financial Officer of InfuSystem and President of Lee Medical.
Mr. Zulueta has over three decades of experience in global strategic and leadership roles with large pharmaceutical companies, particularly at Eli Lilly and Company. At Eli Lilly, he held key leadership positions including Vice President of Global Marketing, Head of the company’s Asia region and, most recently, President of International responsible for all geographies in outside the United States and Canada.
Following the 2022 annual meeting – with the addition of Ms. Enright and Mr. Zulueta, and the scheduled retirements of Mr. Stack and Mr. Zakrzewski – the Amarin Board of Directors will be composed of eight directors, seven of whom are independent.
About Erin Enright
Ms. Enright has been the Managing Partner of Prettybrook Partners since 2012. Previously, she served as Chief Financial Officer of InfuSystem from 2005 to 2007 and President of Lee Medical, a medical device manufacturer, from 2004 to 2013. From 1993 to 2003, Ms. Enright worked at Citigroup, where she was Managing Director of the Equity Capital Markets group. At Citigroup, Ms. Enright was chair of the company’s Institutional Investors Committee, responsible for screening and approving the company’s participation in equity subscriptions and a member of Citigroup’s Global Equity Engagement Committee, responsible reviewing and approving the Company’s subscriptions. She began her career as a lawyer with Wachtell, Lipton, Rosen & Katz.
Ms. Enright is currently Chair of the Board of Dynatronics Corporation, Director of the Board of Medical Facilities Corporation and Chair of the Audit and Investment Committee, Member of the Board of Directors and Chair of the Audit Committee of Brooklyn ImmunoTherapeutics (NASDAQ: BTX), and director of Keystone Dental, a private company where she chairs the audit committee. She previously served as a director at Biolase, Inc., Tigerlabs and Ceelite Corporation.
Ms. Enright earned her AB degree from the School of Public and International Affairs at Princeton University and her JD degree from the University of Chicago School of Law.
About Alfonso “Chito” Zulueta
Prior to Mr. Zulueta’s retirement in 2021, he spent more than three decades at Eli Lilly and Company in various roles of increasing responsibility, including most recently as International Chairman from 2017 until his retirement. He was a corporate officer and member of the executive committee of Eli Lilly and Company.
Mr. Zulueta currently serves on the board of directors of CTS Corporation where he sits on the audit, nominating and governance committees and Syneos Health as well as Glooko and Calidi Biotherapeutics, both private companies. Previously, he was a board member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the US-Japan Business Council.
He received his Bachelor of Arts from De La Salle University in the Philippines and his MBA from the Colgate Darden Graduate School of Business Administration at the University of Virginia.
Amarin is an innovative pharmaceutical company at the forefront of a new paradigm in the management of cardiovascular disease. From our scientific research base, to our focus on clinical trials, and now to our global business expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the USA, Dublin in Ireland, Zug in Switzerland and other countries in Europe, as well as business partners and suppliers worldwide. We are committed to rethinking cardiovascular risk by advancing scientific understanding of the societal impact of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management.
Availability of other information about Amarin
Amarin communicates with its investors and the public using the Company’s website (www.amarincorp.com) and the Investor Relations website (investor.amarincorp.com), including, but not limited to, investor presentations and FAQs, Securities and Exchange Commission (“SEC”) filings, press releases, public conference calls and webcasts. Information posted by Amarin on these channels and websites could be considered material information. Accordingly, Amarin encourages investors, the media and others interested in Amarin to regularly review the information posted on these channels, including the Investor Relations website. This list of channels may be updated from time to time on the Amarin Investor Relations website and may include social media channels. The content of Amarin’s website or such channels, or any other website accessible from its website or such channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
This press release contains forward-looking statements within the meaning of United States securities laws. These forward-looking statements are neither promises nor guarantees and involve substantial risks and uncertainties. A list and description of such risks, uncertainties and other risks associated with an investment in Amarin may be found in Amarin’s filings with the SEC, including Amarin’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and the Quarterly Report on Form 10-Q for the quarter ended March 31, 2022. Existing and potential investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date to which they are made. Amarin undertakes no obligation to update or revise any information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. Amarin’s forward-looking statements do not reflect the potential impact of material transactions that the company may enter into, such as mergers, acquisitions, divestitures, joint ventures or any material agreements that Amarin may enter into, modify or terminate.
Investor Relations Amarin Corporation plc
email@example.com (investor enquiries)
Corporate Communications, Amarin Corporation plc
PR@amarincorp.com (media inquiries)